Aberdeen Group
EVLO

Aberdeen Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Aberdeen Group’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,123
Closed -$716K – 961
2022
Q2 		$716K Buy
+17,123
New +$794K ﹤0.01% 821

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's EVLO Position: Q3 2022 in Review

Aberdeen Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2022, closing a stake of 17,123 shares — an estimated $716K sold.

Aberdeen Group first reported a position in EVLO in Q2 2022 and held it in 1 quarter. The position peaked at $716K in Q2 2022. 41 funds tracked by Wall St. Rank hold EVLO as of Q3 2022.

  • Aberdeen Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Aberdeen Group sold 17,123 Evelo Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $716K.
  • Aberdeen Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Aberdeen Group's Evelo Biosciences, Inc. Common Stock position peaked at $716K in Q2 2022.
  • 41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2022.

Based on Aberdeen Group's 13F filing for Q3 2022, filed 10 Nov 2022.